Biosimilars

In the first systematic review using statistical methods, investigators found switching from a reference biologic to a biosimilar was comparable in safety, but no conclusion on immunogenicity could be drawn.

The House Committee members examined pricing tactics by PBMs and how they are harming patients across the country.

Insulin glargine-yfgn is more affordable than the reference product and patients do not require prescriber authorization switch.

Nuances can lead to frequent areas of confusion.

A collaborative exercise with 16 health care organizations nets millions in savings.

The "interchangeable" designation has created confusion around the difference between biosimilars designated as interchangeable and those that are not.

Clinicians raise concerns about immunogenicity, product quality, and reimbursement for biosimilars.

The importance of findability, accessibility, interoperability, and reusability has become even more significant to academics as government agencies increasingly require data openness and accessibility for funding eligibility.

Manufacturers must find the right balance in drug pricing, so that medications are appealing to both public and private insurers while still remaining profitable throughout their lifecycle.

Enhanced utilization of biosimilar products can have significant impact on reducing the overall cost of health care and potentially reducing out-of-pocket costs for patients.

The seamless integration of artificial intelligence and machine learning has the potential to accelerate research and enhance efficiency in a new era of personalized medicine.

Perhaps the most significant development in the pharmaceutical industry in decades, crops of biosimilars are being approved and are ready for distribution. What lies next, in terms of legislation and the impact on pharmacists, remains to be seen.

The FDA is the first regulatory agency globally to approve natalizumab-sztn as a biosimilar for natalizumab.

The Mylight phase 3 trial confirmed that there was no clinically meaningful differences between aflibercept and its reference biologic, Eylea, for patients with wet macular degeneration.

The launch of adalimumab biosimilars are expected to affect spending in the immunology space.

Pharmacists will have the opportunity to use their knowledge of biosimilars to reinforce their benefits, safety, and efficacy.

Many studies with a stated goal of advancing child health care in administratively-defined minors have no clinical value and may even harm young patients.

Although SB5 is an effective treatment for plaque psoriasis, it is recommended that patients consider the potential risks and adverse effects.

With the continued advancement and approval of cell and gene therapies, the need for trustworthy microbiology quality control solutions is at an all-time high.

Study finds patients with cancer feel reassured that biosimilars provide a safe, adequate, and cost-effective alternative to the pricier reference drug.

In terms of science and technology, the health care community has everything needed to clinically implement pharmacogenomics testing.

A panel of experts discuss the state of biosimilars today and the importance of standardizing knowledge of the field.

An increased demand for methylphenidate products as a result of Adderall shortages has led to a short supply of some popular products, including Ritalin and Concerta.

Pharmacists must carefully consider safety concerns and patient privacy.

Therapeutic drug monitoring is a growing and vital area for pharmacists to become involved in to increase patient success with inflammatory bowel disease remission.

FDA approvals of these biosimilars started in 2016, but only 1 such product has successfully launched.

Express Scripts recently announced the addition of 3 Humira biosimilars to its main formulary.

If finalized, the regulation would potentially reduce prescription nonadherence and accidental misuse.

Adalimumab-adaz HCF in the 100 mg/mL strength is approved for indications that are no longer covered exclusively for the reference Humira after July 2023.

Investigators found that the first biosimilar of trastuzumab, trastuzumab-anns (Kanjinti; Amgen), did maintain a strong and persistent advantage over the other 4 biosimilar entrants.